Rifabutin triple therapy for first‐line and rescue treatment of <i>Helicobacter pylori</i> infection: A systematic review and meta‐analysis
Rachel Gingold‐Belfer, Yaron Niv, Zohar Levi, Doron Boltin
Abstract
Abstract Background and Aim Due to the increasing resistance of Helicobacter pylori , there is a need for novel antibiotic treatment protocols. We aimed to perform a systematic review and meta‐analysis in order to determine the effectiveness and safety of rifabutin triple therapy for H. pylori infection. Methods We performed a systematic review of prospective clinical trials with a treatment arm consisting of proton pump inhibitor, amoxicillin, and rifabutin and a meta‐analysis of randomized controlled trials (RCTs). Results Thirty‐three prospective studies including 44 datasets were identified. Meta‐analysis of four RCTs for rescue treatment found no difference between treatment groups (odds ratio [OR] 0.88, 95% confidence interval [CI] 0.437–1.791, I 2 = 68.1%, P = 0.733). Only one RCT compared rifabutin therapy with control for first‐line treatment of H. pylori infection (OR 3.78, 95% CI 2.44–5.87, P < 0.0001). Treatment was more likely to be successful in Asian versus non‐Asian populations (81.0% vs 72.4%, P = 0.001) and when daily amoxicillin dose was ≥ 3000 mg or proton pump inhibitor dose was ≥ 80 mg or treatment duration was 14 days (80.6% vs 66.0%, P = 0.0001). The overall event rate for adverse effects was 24.8% (729/2937) (95% CI 0.23–0.26), and the pooled OR for adverse effects in the treatment versus control group was 0.93 (95% CI 0.50–1.75) ( I 2 = 79.76, P = 0.82). Conclusion Evidence for the effectiveness of rifabutin for the first‐line treatment of H. pylori infection in adults is limited, and studies comparing rifabutin with conventional first‐line treatments are lacking.